Back

cMPL-Based Purification and Depletion of Human Hematopoietic Stem Cells: Implications for Pre-Transplant Conditioning

Araki, D.; Hong, S.; Linde, N.; Fisk, B.; Redekar, N.; Salisbury-Ruf, C.; Krouse, A.; Engels, T.; Golomb, J.; Dagur, P.; Magnani, D. M.; Wang, Z.; Larochelle, A.

2024-02-28 cell biology
10.1101/2024.02.24.581887 bioRxiv
Show abstract

The transplantation of gene-modified autologous hematopoietic stem and progenitor cells (HSPCs) offers a promising therapeutic approach for hematological and immunological disorders. However, this strategy is often limited by the toxicities associated with traditional conditioning regimens. Antibody-based conditioning strategies targeting cKIT and CD45 antigens have shown potential in mitigating these toxicities, but their long-term safety and efficacy in clinical settings require further validation. In this study, we investigate the thrombopoietin (TPO) receptor, cMPL, as a novel target for conditioning protocols. We demonstrate that high surface expression of cMPL is a hallmark feature of long-term repopulating hematopoietic stem cells (LT-HSCs) within the adult human CD34+ HSPC subset. Targeting the cMPL receptor facilitates the separation of human LT-HSCs from mature progenitors, a delineation not achievable with cKIT. Leveraging this finding, we developed a cMPL-targeting immunotoxin, demonstrating its ability to selectively deplete host cMPLhigh LT-HSCs with a favorable safety profile and rapid clearance within 24 hours post-infusion in rhesus macaques. These findings present significant potential to advance our understanding of human hematopoiesis and enhance the therapeutic outcomes of ex vivo autologous HSPC gene therapies. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=154 SRC="FIGDIR/small/581887v1_ufig1.gif" ALT="Figure 1"> View larger version (48K): org.highwire.dtl.DTLVardef@10b265aorg.highwire.dtl.DTLVardef@102ec94org.highwire.dtl.DTLVardef@fa269dorg.highwire.dtl.DTLVardef@fd2583_HPS_FORMAT_FIGEXP M_FIG O_FLOATNOGraphical abstractC_FLOATNO C_FIG

Matching journals

The top 2 journals account for 50% of the predicted probability mass.

1
Blood Advances
54 papers in training set
Top 0.1%
41.3%
2
Blood
67 papers in training set
Top 0.1%
11.0%
50% of probability mass above
3
Journal of Thrombosis and Haemostasis
28 papers in training set
Top 0.1%
8.8%
4
Haematologica
24 papers in training set
Top 0.1%
3.8%
5
Cell Reports Methods
141 papers in training set
Top 1%
2.6%
6
Cytotherapy
14 papers in training set
Top 0.1%
2.2%
7
Cell Reports
1338 papers in training set
Top 22%
1.9%
8
JCI Insight
241 papers in training set
Top 3%
1.8%
9
Science Advances
1098 papers in training set
Top 16%
1.8%
10
Cell Reports Medicine
140 papers in training set
Top 4%
1.6%
11
PLOS ONE
4510 papers in training set
Top 59%
1.3%
12
Nature Communications
4913 papers in training set
Top 58%
1.0%
13
Experimental Hematology
11 papers in training set
Top 0.2%
0.9%
14
Molecular Therapy - Methods & Clinical Development
38 papers in training set
Top 0.4%
0.9%
15
Stem Cells
28 papers in training set
Top 0.4%
0.8%
16
British Journal of Haematology
15 papers in training set
Top 0.4%
0.8%
17
Communications Biology
886 papers in training set
Top 20%
0.8%
18
Molecular Therapy
71 papers in training set
Top 3%
0.8%
19
Transfusion
18 papers in training set
Top 0.2%
0.7%
20
Stem Cell Research
16 papers in training set
Top 0.2%
0.7%
21
Circulation
66 papers in training set
Top 3%
0.7%
22
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 11%
0.5%
23
Cytometry Part A
30 papers in training set
Top 0.4%
0.5%
24
Clinical Cancer Research
58 papers in training set
Top 2%
0.5%